The silent treatment (original) (raw)

Biotech firms are vying to harness the potential of RNA interference. But will its impact be in finding new disease targets, or in RNA-based drugs? Julie Clayton investigates.

Access through your institution

Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Learn more

Buy this article

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Author information

Author notes

  1. Julie Clayton is a science writer based in Bristol, UK.

    • Julie Clayton

Authors

  1. Julie Clayton
    View author publications
    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Clayton, J. The silent treatment.Nature 431, 599–601 (2004). https://doi.org/10.1038/431599a

Download citation

This article is cited by